Hong Kong-based AI drug discovery company Insilico Medicine and Pharmaceutical company Exelixis has entered an exclusive license agreement for the development and commercialization of an AI-generated cancer treatment, ISM3091.
Under the terms of the license agreement, Exelixis will pay an upfront fee of USD 80 million to Insilico in the third quarter of 2023 and also make future milestone payments and royalties based on the development and commercial success of ISM3091.
The partnership will allow Exelixis to obtain global rights to ISM3091, a small molecule that targets USP1, and offer a differentiated treatment for BRCA-mutated tumors. Additionally, Exelixis aims to accelerate Phase I trial enrollment for ISM3091 through this collaboration.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.